Vaccine adjuvant for treating autoimmune diseases and application thereof

A technology for immune diseases and new uses, applied in the field of vaccine adjuvants for the treatment of autoimmune diseases, can solve the problems of ineffective prevention of diabetes and other problems, and achieve the effect of simple and easy treatment, lower titer, and simple preparation method

Inactive Publication Date: 2018-11-23
INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Existing treatments for type 1 diabetes, such as islet transplantation and insulin injection outside the body, cannot effectively prevent the onset of diabetes
As an

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vaccine adjuvant for treating autoimmune diseases and application thereof
  • Vaccine adjuvant for treating autoimmune diseases and application thereof
  • Vaccine adjuvant for treating autoimmune diseases and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0030]The invention provides a method for preparing polylactic acid-glycolic acid copolymer microspheres loaded with antigen polypeptides, comprising the steps of:

[0031] S1: Dissolve polylactic acid-glycolic acid copolymer in dichloromethane to obtain a dichloromethane solution dissolved with polylactic acid-glycolic acid copolymer; wherein, the mass of polylactic acid-glycolic acid copolymer and the volume of dichloromethane The ratio is (10 ~ 60) mg: (1 ~ 10) mL;

[0032] S2: Dissolving the antigenic polypeptide in ultrapure water to obtain an aqueous solution in which the antigenic polypeptide is dissolved; wherein, the ratio of the mass of the antigenic polypeptide to the volume of water is (0.05-50) mg: (1-100) μL;

[0033] S3: Mix the dichloromethane solution in which the polylactic acid-glycolic acid copolymer is dissolved and the aqueous solution in which the antigenic polypeptide is dissolved, and then sonicate in an ice bath for 1 to 20 minutes, and the ultrasonic...

Embodiment 1

[0039] This example provides a method for preparing polylactic acid-glycolic acid copolymer microspheres loaded with antigen polypeptides, including steps:

[0040] S1: Dissolve 30 mg of polylactic acid-glycolic acid copolymer in 1 mL of dichloromethane to obtain a dichloromethane solution in which polylactic acid-glycolic acid copolymer is dissolved;

[0041] S2: Dissolving 1 mg of the antigenic polypeptide in 100 μL of ultrapure water to obtain an aqueous solution in which the antigenic polypeptide is dissolved;

[0042] S3: Mix the dichloromethane solution in which the polylactic acid-glycolic acid copolymer is dissolved and the aqueous solution in which the antigenic polypeptide is dissolved, and then sonicate in an ice bath for 1 min, and the power of the sonication is 30W, to obtain oil-in-water (w / o) colostrum; , the mass ratio of polylactic acid-glycolic acid copolymer to antigenic polypeptide is 1:0.20;

[0043] S4: After mixing the oil-in-water colostrum and the pol...

Embodiment 2

[0047] The polylactic acid-glycolic acid copolymer microspheres loaded with antigen polypeptide prepared in Example 1 of the present invention were subcutaneously injected into spontaneous type 1 diabetes model mice (non-obese diabetic, NOD mice), and the curative effect was tested.

[0048] 1. Experimental method

[0049] Weaned female non-obese diabetic (NOD) mice were randomly divided into three groups, and there was no statistical difference among the three groups of mice. After normal body weight and blood sugar measurements, the polylactic acid-glycolic acid copolymer microspheres loaded with antigen polypeptide prepared in Example 1 of the present invention (PLGA polypeptide treatment group) were injected subcutaneously, once a week, 100 μg each time, 4 times in total, And a naked peptide treatment group (injection of the same amount of antigen polypeptide) and an untreated blank group (injection of the same amount of phosphate saline, ie PBS solution) were set up. Aft...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a vaccine adjuvant for treating autoimmune diseases and application thereof, and particularly discloses application of a polylactic acid-glycolic acid copolymer to preparing drugs for treating autoimmune diseases by serving as a vaccine adjuvant. The polylactic acid-glycolic acid copolymer is produced to be microballoon spheres to load insulin B chain polypeptide B9-23 toserve as effective antigen, through hypodermic injection, the polylactic acid-glycolic acid copolymer can assist the function of the antigen and achieves the effect of an immunologic adjuvant, the auto-antibody titer in a mouse is reduced, accordingly the antigen can be more effectively assisted to activate proliferation and functions of regulatory T cells in vivo, immune tolerance is induced, andaccordingly attack of 1 type diabetes can be effectively prevented or delayed. In addition, because the 1 type diabetes belongs to the autoimmune diseases, the polylactic acid-glycolic acid copolymercan serve as an adjuvant and applied to other autoimmune diseases.

Description

technical field [0001] The invention relates to the technical field of autoimmune disease medicines, in particular to a vaccine adjuvant for treating autoimmune diseases and its application. Background technique [0002] Autoimmune diseases mainly include rheumatoid arthritis, autoimmune diabetes (also known as type 1 diabetes), autoimmune encephalomyelitis (multiple sclerosis) and lupus erythematosus. The specific cause of the disease is still unknown, but it is usually caused by the body's abnormal immune rejection of its own normal tissues, that is, immune intolerance. If certain means can be used to make the body produce immune tolerance to these self-antigens, avoid the generation of self-antibodies and the timing and attack of T cells on these antigens, then the attack of immune cells on self-antigen-containing tissues can be corrected. [0003] Taking type 1 diabetes as an example, type 1 diabetes is due to the obstacle of self-immune cells in the process of negative...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/39A61K9/50A61K47/34A61K39/00A61P3/10A61P37/04
CPCA61K9/5031A61K39/0008A61K39/39A61K2039/55555A61K2039/57A61P3/10A61P37/04
Inventor 李宸杨静宜冯丹丹孔德领
Owner INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap